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Background: Chemotherapy (CT) combined to radiation therapy 
(RT) is the standard treatment in limited disease small cell lung cancer 
(LDSCLC). Many questions including RT dose, volume, and RT/CT 
sequence of administration remain controversial. We assess the out-
come of patients with LDSCLC.
Methods: From September 1998 to 2006, 69 patients with LDSCLC 
were treated at our institutions. Treatment consisted of CT and 3D 
conformal thoracic irradiation in all patients. Median age was 61 years 
(range: 37-78). Sequential or concomitant CT/RT was given in 47 (68%) 
and 22 (32%) of the patients, respectively. Chemotherapy consisted of 
either cisplatin and etoposide (PE) in 74% of the patients, or ifosfamid, 
cisplatin and etoposide (ICE) in 26%. Clinical target volume (CTV) 
included gross tumor volume and enlarged/involved lymph nodes. In 
23% of the patients, positron emission tomography was used in the 
CTV delineation. The median RT dose was 60 Gy. Prophylactic cranial 
irradiation was given in 47 (68%) patients in complete remission.
Results: All patients have completed full treatment. With a median 
follow-up of 36 months (range: 6-107), 16 patients are alive without 
disease. Median overall survival time was 24 months, with survival 
rates of 29% at 3 years. The 3-year disease-free survival (DFS) and 
locoregional control rates were 23% and 60%, respectively. No sig-
niﬁcant dose-response relationship was found in terms of locoregional 
control or survival. However, patients treated with full-dose sequential 
CT/RT had better outcome than those treated with concomitant treat-
ment (3-year DFS: 27% vs. 13%; p = 0.04; Fig.1). ICE chemotherapy 
resulted with better outcome (3-year overall survival: 41% vs. 25%; 
p = 0.04; Fig.2). No major (CTV v3.0 grade 3 or 4) treatment-related 
morbidity was observed.
Conclusions: Sequential administration of ICE chemotherapy followed 
by 60-Gy 3D conformal RT seems to be better than concomitant PE 
chemotherapy and RT.
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small-cell lung cancer (SCLC) responding to chemotherapy with 
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Background: Despite high response rates following chemo- and 
radiotherapy in SCLC, long term survival remain poor because of high 
incidence and early onset of local and distant recurrence. The role of 
surgery in SCLC is still not deﬁned, but non- randomized data suggest 
an advantage in survival for patients with limited disease. The regimen 
of paclitaxel, etoposide phosphate and carboplatin has shown efﬁ-
cacy and low toxicity in a randomized phase III trial. Objectives: The 
primary objective was to compare overall survival of SCLC patients 
(stage I-III) who responded to TEC followed by surgery and local 
radiotherapy versus local radiotherapy only. 
Regimen: Patients with SCLC stage I-III and functional operability 
were treated with 4 cycles of paclitaxel 135 mg/m2 d 4, etoposide phos-
phate 125 mg/m2 d 1-3 and carboplatin AUC 5, d 4 (q d 22). Patients 
with PR or CR were randomized to local radiotherapy and either brain 
irradiation with 36 Gy ( in case of CR) (arm A) or surgery followed by 
local radiotherapy and brain irradiation (in case of R0/R1 resection). 
(arm B) Results: Due to slow recruitment the study was closed 2004. 
98 patients (72 male/26 female) mainly in good performance status (97 
ECOG 0/1, 1 ECOG 2) entered the study. 39.5% of the patients had 
N0/1 disease, 51% N2 and 6% N3 disease. RR after chemotherapy was 
92.7 % (34.9% CR, 57.8% PR). Hematological toxicity was moderate 
with WBC CTC 3/4 31.6%, anemia CTC 3 5.1% and thrombocyto-
penia CTC 3 3% of patients. Non- hematological toxicity was low. 
69 patients were randomized (36 arm A, 33 arm B) and 21 patients 
underwent surgery with a R0 resection rate of 91.7%. The median dose 
of irradiation in arm B was 56 Gy (46-76 Gy). Toxicity of radiotherapy 
and surgery was low and well manageable. Median survival was 15.2 m 
(Arm A) and 16.0 m (Arm B, p= 0.61). Median PFS was 15.2 m (Arm 
A) and 15.7 m (Arm B, p= 0.79). 
